4,122-share purchase and warrant grant tied to ProMIS (PMN) CSO Neil Cashman

Rhea-AI Filing Summary

ProMIS Neurosciences director and Chief Scientific Officer Neil Cashman reported an indirect purchase of 4,122 common shares at $12.13 per share through Research Capital Corporation, along with warrants to buy 4,122 additional common shares. These securities were acquired on February 3, 2026 under a Securities Purchase Agreement with selected investors.

The warrants to purchase common shares have an exercise price of $14.40 per share and are exercisable immediately. They will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from single ascending dose cohorts of PMN310. The filing also notes that common share figures reflect a one-for-twenty-five reverse split completed on November 28, 2025.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Cashman Neil

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase Common Shares	4,122	$0.00	--
Grant/Award	Common Shares	4,122	$12.13	$50K
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Warrants to purchase Common Shares — 4,122 shares (Indirect, By Research Capital Corporation); Common Shares — 4,122 shares (Indirect, By Research Capital Corporation); Common Shares — 4,532 shares (Direct)

Footnotes (1)

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cashman Neil

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

1920 YONGE STREET, SUITE 200

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A(1)		4,122	A	$12.13(1)	4,122	I	By Research Capital Corporation
Common Shares								4,532(2)	D
Common Shares								664(2)	I	By his spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase Common Shares	$14.4	02/03/2026		A(1)		4,122		02/03/2026	02/03/2031(3)	Common Shares	4,122	(1)	4,122	I	By Research Capital Corporation

Explanation of Responses:

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 4,122 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 4,122 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

2. Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.

3. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

	/s/ Max A. Milbury, Attorney in Fact for Neil Cashman	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ProMIS Neurosciences (PMN) disclose for Neil Cashman?

Neil Cashman reported an indirect acquisition of 4,122 ProMIS Neurosciences common shares through Research Capital Corporation. He also reported related warrants for 4,122 common shares, both obtained under a Securities Purchase Agreement with selected investors dated February 3, 2026.

What was the purchase price for the ProMIS Neurosciences (PMN) shares in this Form 4?

The indirect purchase price was $12.13 per ProMIS Neurosciences common share, acquired through Research Capital Corporation. The same $12.13 price applied to the accompanying common share purchase warrants obtained under the February 3, 2026 Securities Purchase Agreement with selected investors.

What warrants were reported in Neil Cashman’s ProMIS Neurosciences (PMN) Form 4?

The filing reports warrants to purchase 4,122 ProMIS common shares at an exercise price of $14.40 per share. These warrants are exercisable on February 3, 2026 and are held indirectly through Research Capital Corporation associated with Neil Cashman.

When do the ProMIS Neurosciences (PMN) warrants reported by Neil Cashman expire?

The common share warrants expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing providing topline data from single ascending dose cohorts of PMN310, whichever occurs first.

How many ProMIS Neurosciences (PMN) shares does Neil Cashman report owning after the transaction?

After the reported activity, Neil Cashman reports 4,532 common shares held directly and 664 common shares held indirectly by his spouse. He also reports 4,122 common shares and associated warrants held indirectly through Research Capital Corporation.

Did ProMIS Neurosciences (PMN) recently complete a reverse stock split?

Yes. The Form 4 notes that the reported common share amounts reflect a one-for-twenty-five reverse split of ProMIS Neurosciences’ common shares, which was effected on November 28, 2025, adjusting prior share counts accordingly.